66 completed, 14 terminated, 5 active not recruiting, 2 recruiting. 91 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 91 | Completed 66, Terminated 14, Active not recruiting 5, Recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow Epoetin Alfa: new trials by email Literature Review of Epoetin Alfa trials Research Report on Epoetin Alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions Elritercept, Epoetin Alfa - Myelodysplastic Syndrome, Anemia | Phase 3 | Recruiting | Takeda | 300 | 2026-05-21 | 2026-10-19 |
| Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration., Active comparator: European Union licenced epoetin alfa - Anemia of Chronic Kidney Disease | Phase 3 | Not yet recruiting | Megalabs | 280 | 2025-07-01 | 2024-08-19 |
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Active not recruiting | USRC Kidney Research | 2200 | 2024-11-20 | 2026-03-10 |
| ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 402 | 2023-10-24 | 2026-06-30 |
| ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Epoetin Alfa 40000 UNT/ML, Sodium Chloride 0.9% - Trauma, Traumatic Injury | Phase 3 | Recruiting | Australian and New Zealand Intensive Care Research Centre | 2500 | 2020-11-09 | 2025-07-16 |
| Desidustat in the Treatment of Anemia in CKD on Dialysis Patients Desidustat Oral Tablet, Epoetin Alfa - Chronic Kidney Disease Stage 5 on Dialysis | Phase 3 | Completed | Zydus Lifesciences Limited | 392 | 2020-01-04 | 2021-11-24 |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve Luspatercept, Epoetin alfa - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | Celgene | 363 | 2019-01-02 | 2024-11-20 |
| A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS EPREX - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | Groupe Francophone des Myelodysplasies | 124 | 2018-03-26 | 2026-09-11 |
| Traumatic Optic Neuropathy Treatment Trial 2 Recombinant human erythropoietin - Traumatic Optic Neuropathy | Phase 3 | Completed | Iran University of Medical Sciences | 93 | 2018-01-06 | 2024-03-08 |
| High-dose Erythropoietin for Asphyxia and Encephalopathy Normal saline placebo, Erythropoietin - Neonatal Encephalopathy, Birth Asphyxia | Phase 3 | Completed | University of California, San Francisco | 500 | 2017-01-01 | 2023-01-30 |
| Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients CinnaPoietin®, Eprex®, Nephrovit - Anemia in End-Stage Renal Disease | Phase 3 | Completed | Cinnagen | 156 | 2016-06-22 | 2019-12-18 |
| PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns Epoetin Alfa, Normal saline - Hypoxic-Ischemic Encephalopathy | Phase 3 | Completed | University of Sydney | 313 | 2016-05-14 | 2024-06-05 |
| To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) EPORON, EPREX - Anemia of Chronic Kidney Disease | Phase 3 | Unknown | Dong-A ST Co., Ltd. | 214 | 2016-03-01 | 2019-12-10 |
| Study to Compare the Safety and Efficacy of UB-851 and Eprex® UB-851, Eprex - Renal Anemia | Phase 3 | Completed | UBI Pharma Inc. | 269 | 2016-03-01 | 2023-12-06 |
| FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease FG-4592, Epoetin Alfa - Anemia | Phase 3 | Completed | Kyntra Bio | 305 | 2015-12-01 | 2017-08-24 |
| Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study) EPREX®, EPIAO® - Renal Anemia | Phase 3 | Completed | Shenyang Sunshine Pharmaceutical Co., LTD. | 207 | 2015-12-01 | 2022-11-23 |
| Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Epoetin Alfa, Roxadustat - CKD Anemia in Stable Dialysis Patients | Phase 3 | Completed | Kyntra Bio | 741 | 2015-01-15 | 2021-10-29 |
| Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Roxadustat, Epoetin alfa, Darbepoetin alfa - Anemia, End Stage Renal Disease (ESRD) | Phase 3 | Completed | Astellas Pharma Europe B.V. | 838 | 2014-11-21 | 2024-11-27 |
| Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. Roxadustat, Epoetin alfa - Anemia | Phase 3 | Completed | AstraZeneca | 2133 | 2014-07-01 | 2019-12-16 |
| Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants Roxadustat, Epoetin Alfa - Anemia in Incident Dialysis Patients | Phase 3 | Completed | Kyntra Bio | 1043 | 2014-02-11 | 2021-10-01 |
Showing 20 of 91. Sign in to see all of them.
Anemia (65) · Renal Insufficiency, Chronic (16) · Kidney Failure, Chronic (9) · Neoplasms (9) · Leukemia (7) · Multiple Myeloma (7) · Myelodysplastic Syndromes (7) · Breast Neoplasms (6) · Lymphoma (6) · Neoplasms, Plasma Cell (5) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lung Neoplasms (3) · Lymphoma, Follicular (3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (23) · Hoffmann-La Roche (9) · Amgen (4) · Sandoz (4) · Janssen-Ortho Inc., Canada (3) · Kyntra Bio (3) · Ortho Biotech Products, L.P. (3) · Affymax (2) · Alliance for Clinical Trials in Oncology (2) · Australian and New Zealand Intensive Care Research Centre (2) · M.D. Anderson Cancer Center (2) · Pfizer (2) · Astellas Pharma Europe B.V. (1) · AstraZeneca (1) · Azidus Brasil (1)
United States (38) · Germany (15) · France (12) · Poland (12) · Spain (12) · Italy (10) · Australia (9) · Canada (9) · United Kingdom (9) · Hungary (8) · Russia (8) · Belgium (7) · Mexico (7) · Puerto Rico (7) · Romania (7)
Vice President, Clinical Development (2) · Alistair D Nichol, MD (1) · Amit K Verma (1) · Andrea Vetter, Dr. (1) · Anna Sureda (1) · Arthur William Blackstock, MD (1) · Associate Professor Craig French (1) · Bolong Miao, Doctoral (1)
PMID 36005278, PMID 36791280, PMID 38363466, PMID 36749544, PMID 16710026, PMID 23343061, PMID 23343062, PMID 26452709, PMID 26965694, PMID 32734207, PMID 15901766, PMID 16087945, PMID 16253719, PMID 16505427, PMID 16553139, PMID 16782926, PMID 16877725, PMID 17312332, PMID 17716826, PMID 17804841, PMID 17950856, PMID 19808215, PMID 19927096, PMID 20077249, PMID 21675055, PMID 23924660, PMID 25528574, PMID 25884605, PMID 26038709, PMID 26858335, PMID 29084409, PMID 30132785, PMID 30253403, PMID 31340116, PMID 33439748, PMID 33566466, PMID 34144032, PMID 35361724, PMID 35830641, PMID 36451454, PMID 37019334, PMID 37311468, PMID 37418263, PMID 37698478, PMID 37742617, PMID 38006967, PMID 38360261, PMID 38984984, PMID 39038479, PMID 39301879
2005 (1), 2009 (1), 2025 (1), U10CA021115 (1), U10CA027469 (1), U10CA180820 (1), U24CA196172 (1)